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ABSTRACT
Nitric oxide (NO) exerts conflicting effect on tumor growth and progression, 
depending on its concentration. We aimed to characterize the anti-cancer activity 
of a new NO donor, Ni(SalPipNONO) belonging to the class of metal-nonoates, in 
epithelial derived tumor cells, finally exploring its antiangiogenic properties. Tumor 
epithelial cells were screened to evaluate the cytotoxic effect of Ni(SalPipNONO), 
which was able to inhibit cell proliferation in a dose dependent manner, being more 
effective than the commercial DETA/NO. The human lung carcinoma cells A549 were 
chosen as model to study the anti-cancer mechanisms exerted by the compound. In 
these cells, Ni(SalPipNONO) inhibited clonogenicity and cell invasion, while promoting 
apoptosis. The antitumor activity was partly due to NO-cGMP dependent pathway, 
contributing to reduced cell number and apoptosis, and partly to the salicylaldehyde 
moiety and reactive oxygen species (ROS) activated ERK1/2 signaling converging 
on p53 dependent caspase-3 cleavage. An additional contribution by downstream 
cycloxygenase-2 (COX-2) derived cyclopentenones may explain the tumor inhibitory 
activities. As NO has been described to affect tumor angiogenesis, we checked this 
activity both on tumor and endothelial cell co-cultures and in Matrigel in vivo assay. 
Our data document that Ni(SalPipNONO) was able to both reduce angiogenic factor 
expression by tumor cells acting on hypoxia inducible factor-1α (HIF-1 α) level, and 
endothelial cell functions related to angiogenesis. Collectively, these data confirm the 
potential use of NO donors and in particular Ni(SalPipNONO) acting through multiple 
mechanisms, as an agent to be further developed to be used alone or in combination 
with conventional therapy.
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INTRODUCTION
From the first studies on the effect of nitric oxide 
(NO) in cancer biology, this mediator emerged as a 
biphasic modulator, behaving both as an antineoplastic 
and proneoplastic stimulus [1]. The bimodal actions of NO 
can be explained through the duration of NO exposure, 
the cellular microenvironment, NO flux, tumor cell 
proliferation rate, occurrence of oxidizing and reducing 
processes [1]. 
The established biochemical/cellular events 
elicited by NO against tumor development are essentially 
inhibition of cell proliferation and proapoptotic events, 
and vascular effects including anti-angiogenesis. The 
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proapoptotic events described in the literature relate 
to p53 upregulation and accumulation, degradation 
of antiapoptotic mediators, mitochondrial membrane 
permeability, and induction of cytochrome c release [2–4]. 
In cancer cells, NO released by NO donors or nitric oxide 
synthase (NOS) has been suggested to activate p53 via 
DNA damage by peroxynitrite (ONOO–) [5–7].
The use of NO donors can improve vascular 
flow, and anticancer drug delivery in hypoxic tissue, 
favoring the penetration of chemotherapy in tumor tissue 
and improving their cytotoxic effects [8–10]. Indeed, 
an increase in response to radiotherapy [10, 11] and 
chemotherapy [12, 13] has been reported.
Tumor tissue is characterized by low oxygen tension, 
a condition that promotes the activation and stabilization 
of hypoxia inducible factor-1α (HIF-1α) which, in turn, 
controls the transcription of vascular endothelial growth 
factor (VEGF), thus promoting angiogenesis, tumor 
growth and metastasis [14, 15]. NO has been reported to 
inhibit the expression of HIF-1α through the activation 
of HIF-1-prolyl hydroxylases and its proteasomal 
degradation [16–19]. NO, by reducing HIF-1α dependent 
VEGF levels, at the end can improve the delivery of 
antitumor drugs, through vascular normalization and 
reversion of the oncotic pressure gradient [20].
Recently, a new family of metal-nonoates has been 
developed [21] and characterized for their potential use 
in cardiovascular diseases, characterized by endothelial 
dysfunction, obtaining a vascular protective effect 
at nanomolar concentrations [22, 23]. Here, we have 
evaluated the antitumor activity of a member of this 
class, Ni(SalPipNONO), assessing the antitumor efficacy 
in two epithelial derived tumor cells, A549 and HT29, 
representative of lung and colon carcinoma, respectively. 
Ni(SalPipNONO) was characterized for different 
mechanisms related to tumor hallmarks as well as for its 
antiangiogenic effects on tumor and endothelial cells.
RESULTS
Antitumor effects and mechanisms of action of 
Ni(SalPipNONO) 
To test the effect of novel NO donor, human lung 
carcinoma cells A549 cells were exposed for 72 h to 
Ni(SalPipNONO) and DETA/NO used in a wide range 
of concentrations (0.001–1 mM) and cell viability was 
assessed by the MTT assay. The experiment was performed 
in 0.1 and 2% FBS (Figure 1A and 1B). Ni(SalPipNONO), 
compared with equimolar concentrations of DETA/
NO, was more effective in reducing cell number, 
in particular in the range 0.1–1 mM. The EC50 for 
Ni(SalPipNONO) were 0.26 and 0.37 mM in 0.1 and 2% 
serum, respectively. To assess the antiproliferative effect 
of the nonoate, BrdU incorporation assay were performed 
after 24 h of Ni(SalPipNONO) treatment in 0.1 and 2% 
FBS (Figure 2C). In both experimental conditions, the 
viability of A549 cells was less than 50% after exposure 
to 1 mM of NO donors. These experiments show that 
Ni(SalPipNONO) exerted its antiproliferative effects at 
doses near 0.5 mM, while at 1 mM it revealed a cytotoxic 
action. 
Similar results were obtained with the human colon 
adenocarconma cells HT29 (Supplementary Figure 1A 
and 1B). 
When tested on normal cells, namely HaCaT 
keratinocytes, Ni(SalPipNONO) exerted antiproliferative 
action only on sparse cells exposed to 2% serum 
(Supplementary Figure 2A). Interestingly, when the 
nonoate was tested on confluent cells exposed to low 
serum concentration, a more physiological condition, it 
did not inhibit cell proliferation (Supplementary Figure 
2B) until 1 mM of drug. 
Next, the cellular and biochemical characterization 
of Ni(SalPipNONO) antitumor activity was performed in 
A549 cells, using 0.5 mM concentration of the NO donor 
and control molecules. This concentration corresponded 
to a significant antiproliferative effects (on proliferating 
tumor cells) which allowed to study biochemical effects.
Beside cytotoxic/antiproliferative activity, we have 
studied the capability of metal-nonoate to interfere with 
clonogenicity of A549 cells. Data showed that at 0.5 and 1 
mM of Ni(SalPipNONO) the surviving fraction was reduced 
of >90% with respect to basal, while DETA/NO exerted a 
modest, non-significant, effect (Figure 2A and 2B). 
It is well known that metastasis of cancer cells 
involves cell invasiveness [24]. By using the Boyden 
chamber and gelatin coated filters, we have investigated 
the activity of NO donors on cell migration. As shown 
in Figure 2C, the test has been carried out in the 
presence of low and high concentration of an unspecific 
chemoattractant agent, i.e. serum. In both conditions, 
after 18 h of exposure to 0.5 mM Ni(SalPipNONO), we 
could detect halving of cells migrated across filter toward 
the lower chamber. The inhibitory effect of DETA/NO 
was evident only when cells were stimulated by a serum 
gradient.
From all these data, the metal-nonoate 
Ni(SalPipNONO) at sub-millimolar concentration 
showed an antiproliferative effect on lung cancer cells, 
accompanied by reduced clonogenicity and invasiveness.
We then evaluated the mechanisms responsible for 
the tumor inhibitory effects. 
First, we evaluated the involvement of the classical 
soluble guanylate cyclase (sGC)/cGMP pathway by the 
use of ODQ. The preincubation with ODQ (10 µM, 30 min 
before Ni(SalPipNONO) only partially reverted the NO 
donor cytotoxic effect (Figure 3A), suggesting that other 
pathways or chemical components of the molecule could 
be responsible of the antitumor actions. Oxidative stress 
and ROS production have been described to contribute 
to the cytotoxic effect of high doses on NO, due to its 
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radical nature [6, 7]. We measured ROS levels in A549 
cells stimulated with the metal-nonoate in different serum 
concentrations by means of the fluorophore DCFH2-DA 
and we found a significant burst in ROS production that 
was abolished by NAC pretreatment (Figure 3B). 
Next, to evaluate the portion of molecule responsible 
of cytotoxic activity, we have tested different compounds 
with or without the NONO or the salicylaldehyde 
moiety at equimolar concentration. The compounds 
with salicylaldehyde group exerted the greater cytotoxic 
action (probably due to its metabolism in salicylic acid), 
with a synergetic effect with NONO group (Figure 3C). 
Ultimately, we can speculate that both the NONO group 
and salicylaldehyde moiety concur to the cytotoxic action. 
Since the compound devoid of NONO group did not create 
an oxidative environment in cells (Figure 3B), a double 
mechanism of cytotoxic action could be hypothesized: the 
NONO group induces oxidative stress, and salicylaldehyde 
exerts an additional mechanism.
Since COX-2 derived prostanoids can influence 
tumor development, and inflammation is one of the 
tumor hallmarks [24], we have evaluated the activity of 
Ni(SalPipNONO) on COX-2 protein levels. As reported 
in Figure 4A, COX-2 was upregulated by 0.5 mM 
concentration of the metal-nonoate, but not by DETA/NO. 
From a mechanistic point of view, the inhibition of COX-
2 activity by NS398 partially reverted the metal-nonoate 
cytotoxic effect (Figure 4B), hypothesising that inhibitory 
prostanoids could contribute to antitumor activity. Indeed, 
cyclopentenones as 15d-PGJ2 have been reported to 
inhibit cell growth and induce apoptosis in various tumors 
[25–29]. In our tumor model, when cells were exposed 
to exogenous 15d-PGJ2, a dose dependent inhibition of 
cell chemotaxis toward 10% serum was detected (Figure 
4C), suggesting a contribution of endogenously processed 
inhibitory prostanoids.
The capability of NO to induce apoptosis is widely 
reported in literature [1, 2, 5, 6], thus to understand the 
mechanisms of cell number reduction promoted by 
Ni(SalPipNONO), the expression of apoptotic markers 
was evaluated. Exposure of cells to Ni(SalPipNONO) 
(0.5 mM, 15 min) doubled cytochrome c levels (Figure 
5A), maybe through the reactive species generated by 
NO (like peroxynitrite and ROS) that cause opening of 
the permeability transition pore of mitochondria [2, 30]. 
Moreover, it is known that ROS activate ERK1/2 [31] and 
Figure 1: Ni(SalPipNONO) dose dependently inhibits tumor cell growth. A549 cells were treated with increasing concentrations 
of NO donors (0.001–1 mM) in the presence of 0.1% (A) and 2% (B) serum and cell viability was evaluated by MTT after 72 h. Data are 
reported as relative absorbance ± SD (n = 3). Cell proliferation after 24 h was assessed by BrdU incorporation assay (C). Data are reported 
as luminescence ± SD (n = 3). The highest concentration of DMSO (1% v/v) used as vehicle was reported as control. *p < 0.05, **p < 0.01 
and ***p < 0.001 vs untreated cells. #p < 0.05, ##p < 0.01 and ###p < 0.001 Ni(SalPipNONO) vs DETA/NO.
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Figure 2: Ni(SalPipNONO) inhibits clonogenicity and invasiveness of A549 cells. (A) A549 monolayers were treated with test 
NO donors for 48 h. After trypsinization cells were seeded at the density of 500 cells/well in 24 multi-well plates and let to form colonies 
for 10 days. Pictures of cultures were taken after fixation and staining. (B) The number of colonies formed by >30 cells were randomly 
counted/well and the graph represents the surviving fraction obtained giving 100% to untreated cells. (n = 3). ***p < 0.001 vs untreated cells 
and ###p < 0.001 Ni(SalPipNONO) vs DETA/NO. (C) Cell migration through a gelatin coated filter toward serum was assessed following 
incubation with Ni(SalPipNONO) or DETA/NO (0.5 mM) for 18 h. Data are reported as number of cells counted/well. (n = 3). **p < 0.01 
and ***p < 0.001 vs untreated cells.
Figure 3: Molecular mechanisms responsible for cytotoxicity. (A) sGC/cGMP involvement was evaluated by the use of 10 µM 
ODQ (30 min pretreatment) in survival assay of A549 cells treated with 0.5 mM Ni(SalPipNONO). Cell survival was evaluated by MTT. 
*p < 0.05, ***p < 0.001 vs untreated cells. (B) Oxidative stress involvement was assessed by measuring ROS levels in A549 cells treated 
with Ni(SalPipNONO) and Ni(SalPip)Cl in the presence of different serum concentrations. NAC pretreatment (5 mM, 30 min) was used 
as a ROS scavenger. ***p < 0.001 vs untreated cells. (C) The contribution of NONO or salicylaldehyde moiety was evaluated by testing the 
cytotoxicity of molecules devoid of the NONO or salicylaldehyde group (each at 0.5 mM). Data are reported as relative absorbance of the 
MTT assay after 72 h incubation. **p < 0.01 and ***p < 0.001 vs untreated cells.
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in A549 cells Ni(SalPipNONO), but not DETA/NO, strongly 
increased pERK1/2 after 30 min of incubation (Figure 5B). 
ERK1/2 on its turn upregulates p53 [32–34] and in our 
experiments p53 maximum level was obtained after 60 min 
of incubation with the metal-nonoate (Figure 5C). Indeed, 
the preincubation of the cells with MEK inhibitor U0126 
interfered with p53 upregulation (Figure 5D).
The ultimate event downstream to cytochrome c 
release is caspase 3 activation that leads to DNA cleavage 
and apoptosis [35]. Our data show a maximum production 
(triple respect basal) of cleaved-caspase 3 after 4 h of 
exposure with Ni(SalPipNONO) (Figure 5E), an effect 
which was completely abolished by the preincubation with 
the p53 inhibitor PT-α (Figure 5F). 
From all these data it results that Ni(SalPipNONO) 
is able to impair cell migration and reduce cell number and 
survival by activating the apoptosis pathway that passes 
through ROS production and COX-2 cyclopentenone 
activation, beside the partial involvement of the sGC/
cGMP conventional signaling. 
Antiangiogenic activity by Ni(SalPipNONO) on 
tumor and endothelial cells
HIF-1α expression and proangiogenic factor levels 
are correlated with an increased risk of mortality in several 
types of carcinoma [14]. In A549 cells, we could find 
HIF-1α detectable levels already in normoxic condition 
(Figure 6A). When A549 cells were treated for 24 h with 
Ni(SalPipNONO), there was a substantial decrease of HIF-
1α expression and a consequent reduction of VEGF levels 
(Figure 6A). These results demonstrate that the metal-
nonoate reduces the angiogenetic signals in tumor cells. 
We then assessed whether the antiangiogenic 
property was directly induced in endothelial cells. HUVEC 
were exposed to VEGF (20 ng/ml) in the presence of 
Ni(SalPipNONO). Interestingly, at 0.1 mM the NO donor 
completely abolished VEGF induced proliferation (Figure 
6B). The antiangiogenic activity of Ni(SalPipNONO) 
was evident also in an in vivo angiogenesis assay as the 
subcutaneous Matrigel plug implant. After 10 days, the 
presence of metal-nonoate abolished the vascularization 
produced by VEGF, as documented by representative 
pictures and hemoglobin content in the plugs (Figure 6C 
and 6D).
Co-culture experiments with tumor and endothelial 
cells were set up to strengthen the above results. 
Endothelial cell organization on Matrigel layers was 
evaluated in the presence of tumor cells grown on 
transwell inserts and treated or not with Ni(SalPipNONO). 
In the presence of untreated A549, in 18 h HUVEC formed 
net-like structures, which were impaired when tumor cells 
were treated with the NO donor (Figure 7A).Within the 
same time of incubation, a reduction in VEGF expression 
Figure 4: Ni(SalPipNONO) activates the COX-2 pathway. (A) A549 cells were treated with Ni(SalPipNONO) or DETA/NO (0.5 
mM) for 4 h. COX-2 expression was evaluated by western blot. ***p < 0.001 vs untreated cells. (B) The involvement of COX-2 activity 
on NO donor induced cytotoxicity was evaluated by means of NS398 (10 μM, 30 min pretreatment) incubation and MTT assay. *p < 0.05 
and ***p < 0.001 vs untreated cells. (C) Tumor cell migration toward serum was evaluated in cells treated with increasing concentrations of 
15d-PGJ2. 
*p < 0.05, **p < 0.01 and ***p < 0.001 vs untreated cells.
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was observed after exposure of tumor cells to exogenous 
15d-PGJ2 (Figure 7B). 
These data in the whole demonstrate that the 
antiangiogenic activity of Ni(SalPipNONO) is both direct 
on endothelial cells and indirect on tumor cells which were 
not able to upregulate VEGF, probably through a COX-2/
cyclopentenone dependent mechanism.
DISCUSSION
Here we describe for the first time the antitumor 
efficacy of novel metal-nonoates, in particular 
Ni(SalPipNONO) on A549 tumor cells, characterizing 
the cellular and biochemical profile of the NO donor. We 
have found the cytotoxic activity of Ni(SalPipNONO) at 
doses higher than 0.1 mM, accompanied by inhibition of 
tumor clonogenicity and invasiveness, hallmarks typical 
of malignant tumors. From a mechanistic point of view, 
multiple pathways are responsible for the antitumor 
and proapoptotic events: sGC/cGMP activation; ROS 
production/p-ERK1/2 and cytochrome c/p53 pathway; 
COX-2/cyclopentenone contribution.
The literature reports the proapoptotic effect by 
various NO donors in tumors, contributing to radio-, 
chemosensibilitazion and photodynamic therapy 
[36–41]. Nitroglycerin (NTG) treatment was reported to 
Figure 5: Ni(SalPipNONO) induces signaling related to apoptosis. A549 cells are treated with Ni(SalPipNONO) or DETA/
NO (0.5 mM) for various times ((A) 15 min; (B) 30 min; (C) and (D) 1 h; (E) and (F) 4 h). When inhibitors (U0126 or PT-α, each at 
10 µM) are used, cells are pretreated for 30 min before stimulation with NO donors. The key signals are evaluated by western blot, using beta 
actin, total ERK1/2 or total caspase-3 as controls, when appropriate. Blots are representative of at least 3 with overlapping results. *p < 0.05, 
**p < 0.01 and ***p < 0.001 vs untreated cells. ##p < 0.01 and ###p < 0.001 vs Ni(SalPipNONO) alone.
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significantly increase p53 phosphorylation at serine 15, 
and to enhance chemosensitivity to cisplatin in animal 
model of pathology [42]. Additional mechanisms, 
demonstrated following DETA/NO treatment, were 
S-nitrosylation and nuclear accumulation of p53 and start 
of intrinsic and extrinsic apoptotic pathway [43].
The influence of the conventional sGC/cGMP 
pathway is only marginal, since the block of the cascade 
with ODQ only partially reverted the cytotoxic effect of 
the metal-nonoate.
Here we demonstrate that Ni(SalPipNONO) 
promotes ERK1/2 phosphorylation, possibly through 
NO associated-ROS production. NO-induced oxidative 
stress influences MAPK dependent p53 upregulation 
and activation ultimately leading to caspase-3 cleavage. 
This effect is typical of Ni(SalPipNONO), since DETA/
NO has lower capability to activate the MAPK pathway 
and apoptosis signalling and the compound devoid of the 
NONO group does not elicit an oxidative burst. 
It is known that ROS mediated activation of ERK1/2 
is able to activate the apoptotic pathway by antitumor 
agents [31]. ERK is part of the MAPK superfamily, and 
is well known for its ability to control cell survival in 
response to external stimuli [33, 34]. Several reports have 
found more complex roles for ERK pathway, in which 
the increase of ERK activity might promote apoptosis in 
Figure 6: Ni(SalPipNONO) has antiangiogenic activities. (A) A549 cells were treated with Ni(SalPipNONO) 0.5 mM for 24 
h and HIF-1α and VEGF protein expression was evaluated by western blot. *p < 0.05 and ***p < 0.001 vs untreated cells. (B) Direct 
antiagiogenic activity of Ni(SalPipNONO) on cultured endothelial cells. HUVEC were treated with VEGF (20 ng/ml) in the absence/
presence of Ni(SalPipNONO) 0.1 mM. The number of cells was counted after 48 h following cell fixation and staining. ***p < 0.001 vs 
untreated cells. ###p < 0.01 vs VEGF alone. (C) Ni(SalPipNONO) exerts antiangionic activity in vivo. Mice were subcutaneously implanted 
with Matrigel containing VEGF (300 ng) in the absence or presence of 0.5 mM Ni(SalPipNONO). Plugs were removed after 10 days. 
Pictures are representative plugs out of 3, while the graph (D) reports hemoglobin content quantified by Drabkin reagent (n = 3 plugs). 
***p < 0.001 vs VEGF alone.
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specific environments. Protein kinase pathways such as 
the MAPK pathway are major oxidative stress-sensitive 
pathways in most cell types [45]. In particular, ERK is 
selectively activated in neuronal and renal epithelial 
cells upon exposure to oxidative stress and toxic agents 
such as cisplatin, and inhibition of the ERK pathway has 
been reported to block apoptosis [46]. Several studies 
have reported that curcumin potentiates ROS-dependent 
ERK activation and lethality in irradiated human cervical 
tumor cells [47] and that cisplatin-induced ERK activation 
is partly mediated through ROS generation [48]. In the 
current study, nonoate treatment induces a ROS burst and 
significantly increases ERK1/2 phosphorylation in A549 
cancer cells. These results seem to be consistent with 
several earlier studies, in which increased ERK activity 
by reactive nitrogen  species was linked to the induction 
of cell death [49].
The inhibitor of p53 PT-α blocked the 
apoptosome-mediated processing and activation of 
caspase-9 and -3 without interfering with the activation 
of mitochondria [50]. Our data show that apoptosis 
occurs via a p53-dependent mechanism that takes place 
upstream of mitochondria and involves cytochrome c 
release. Indeed, it is known that the reactive species 
generated by high levels of NO (both peroxynitrite and 
ROS) cause opening of the permeability transition pore 
of mitochondria [2, 30].
We have then evaluated the contribution of 
endogenous prostanoid pathway in the anti-tumor and 
antiangiogenic effect of the metal-nonoate.Among the 
COX-2 derived prostanoids, the pro-inflammatory PGE2 
has a predominant role in promoting tumor growth [51]. 
However, both LOX-and COX-derived products can 
act as endogenous ligands of anti-proliferative and anti-
tumorigenic receptor(s), as PPAR-γ. The cyclopentenone 
prostaglandins PGA2, PGA1, and PGJ2are formed by 
dehydration within the cyclopentane ring of PGE2, PGE1, 
and PGD2. PGJ2 is metabolized further to yield D12-
PGJ2 and 15-deoxy-D12,14-PGJ2 (15d-PGJ2). Various 
compounds within the cyclopentenone prostaglandin 
family possess potent anti-inflammatory, anti-neoplastic, 
and anti-viral activity. Among cyclopentenones, 15d-PGJ2 
has attracted our attention.15d-PGJ2, given exogenously, 
reproduces the antitumor activity of the metal-nonoate. 
15d-PGJ2has been show to inhibit angiogenesis via 
suppression of pro-inflammatory enzymes and cytokines, 
even if stimulatory functions on tumor angiogenesis have 
been reported [52]. In human umbilical vein endothelial 
cells 15d-PGJ2 induced apoptosis via PPAR γ-dependent 
mechanisms [53]. 
Figure 7: Ni(SalPipNONO) exerts antiangiogenic activity in a co-culture system. (A) A549 cells were seeded on transwell 
inserts and treated or not with 0.5 mM Ni(SalPipNONO) for 54 h. Then the inserts (with tumor conditioned medium) were transferred on 
multiplates with HUVEC seeded on top of a Matrigel layer. Incubation continued with further 18 h. Pictures of HUVEC network were 
taken [a. medium conditioned by not treated A549; b. medium conditioned by A549 treated with Ni(SalPipNONO)] and are representative 
of 3 experiments. (B) Expression of VEGF by tumor cells exposed for 8 h to 10 µM 15d-PGJ2. The blot is representative of 3 with similar 
results. ***p < 0.001 vs untreated cells.
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The cyclopentenone involvement leads us to 
investigate the mechanisms related to the antiangiogenic 
activity of the metal-nonoate. Our in vitro and in 
vivo results document the antiangiogenic activity of 
Ni(SalPipNONO). Interestingly, the antiangiogenic 
activity of Ni(SalPipNONO) is both direct on endothelial 
cells and indirect on tumor cells via upregulation of VEGF. 
In the first ones it directly abrogates VEGF induced 
proliferative effect, while in tumor cells the nonoate 
inhibits HIF-1α dependent VEGF upregulation. An 
additional contribution of cyclopentenones as 15d-PGJ2 
in preventing VEGF expression is here demonstrated.
A direct antiangiogenic activity by exogenous NO 
has been reported with other NO donors. In vitro assay 
with cultured endothelial cells revealed that the NO 
hybrid compound NCX-4016, significantly inhibited 
angiogenesis in a dose-dependent manner, with almost 
complete inhibition at a 100 μM concentration [54]. And 
recently, alteration of the expression of angiogenic genes 
has been described in hepatoma cells in response to NO 
donors, in particular an increase in thrombospondin-1 
and tissue inhibitors of metalloprotease-1 [55], known 
inhibitors of angiogenesis and tumor cell migration. 
In conclusion, these data confirm the potential use 
of NO donors and in particular Ni(SalPipNONO) acting 
through multiple mechanisms, as chemotherapeutic agents 
to be further developed in order to be used alone or in 
combination with anticancer conventional therapy. The 
results of a randomized phase II clinical trial have been 
reported, documenting the feasibility of the concurrent use 
of NTG with chemotherapy and radiotherapy in locally 
advanced non-small cell lung cancer to increase chemo- 
and radiosensitivity with an acceptable toxicity profile 
[56]. Interestingly, the overall survival was associated 
to reduced levels of circulating VEGF. Accordingly, a 
retrospective study suggested that application of NTG plus 
docetaxel and carboplatin in patients with operable lung 
adenocarcinoma increases the response with decreased 
expression of HIF-1α and VEGF [57], supporting an 
antiangiogenic activity.
MATERIALS AND METHODS
Drugs used 
The metal-nonoates Ni(SalPipNONO), 
Ni(PipNONO)Cl and Ni(SalPip)Cl have been synthetized 
and characterized by Noxamet Ltd (Milan, Italy) as 
previously reported [21]. DETA/NO was from Sigma-
Aldrich (St. Louis, MO, USA). All NO donors and 
control compounds were dissolved in DMSO (100 mM 
solution). Matrigel (growth factors and phenol red-free) 
was from Becton Dickinson (Waltham, MA, USA). 
VEGF was from R&D Systems (Minneapolis, MN, USA). 
The cyclopentenone prostaglandin 15-deoxy-D12,14-
prostaglandin J2 (15d-PGJ2) was from Cayman Chemical 
(Ann Arbor, MI, USA).
The cyclic pifithrin-alpha (PT-α, a cell 
permeable and potent p53 transcriptional inhibitor) 
[50] was from Sigma Life Science (Milan, Italy). The 
MEK inhibitor U0126 (1,4-diamino-2,3-dicyano-
1,4-bis(2-aminophenylthio)butadiene) and NS398, 
a cycloxygenase-2 (COX-2) inhibitor, were from 
Calbiochem (Milan, Italy). N-acetyl-L-cysteine (NAC) 
was from Sigma-Aldrich (St. Louis, MO, USA). 
Cell cultures
The human lung carcinoma A549 cells were 
obtained from European Collection of Cell Cultures 
(Salisbury, UK). HT-29, the human colorectal 
adenocarcinomacells, were obtained from the American 
Type Culture Collection. HaCaT immortalized human 
keratinocytes were chosen as human normal cell controls. 
HaCaT cells (passages 3–7) were acquired from Voden 
Medical (Meda, MB, Italy). Cells were maintained in 
DMEM (Sigma-Aldrich) supplemented with 10% fetal 
bovine serum (FBS) (Hyclone, Celbio, Milan, Italy) 
and 2 mM glutamine, 100 units penicillin and 0.1 mg/l 
streptomycin (Sigma Aldrich, St. Louis, MO, USA).
Human umbilical vein endothelial cells (HUVEC) 
were purchased from Promocell (Heidelberg, Germany) 
and were grown in endothelial growth medium (EGM-2), 
containing VEGF, R3-IGF-1, hEGF, hFGF, hydrocortisone, 
ascorbic acid, heparin and GA-1000 (Lonza, Basel, 
Switzerland), 10% FBS and 2 mM glutamine, 100 units/
ml penicillin and 0.1 mg/ml streptomycin (Sigma Aldrich, 
St. Louis, MO, USA). Cells were split 1:3 twice a week, 
and used until passage 10. Cells were cultured at 37° C in 
5% CO2. 
MTT assay
Tumor cell survivalwas quantified by MTT assay. 
3 × 103 cells were seeded in 96-multiwell plates in medium 
with 10% serum and after adherence were exposed to 
Ni(SalPipNONO) or DETA/NO (0.001 to 1 mM, 72 h) in 
0.1% or 2% FBS. Where indicated, cells were pre-treated 
with 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ) 
(10 µM) and NS398 (10 µM). Medium was removed and 
cells were incubated for 4 h with fresh medium in the 
presence of 1.2 mM 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT). After solubilization 
in DMSO, absorbance was measured with a microplate 
absorbance reader (Infinite 200 Pro, Tecan Life Sciences, 
Switzerland) at 540 nm. Data are reported as 540 nm 
relative absorbance/well [58].
BrdU incorporation assay
Cell proliferation was determined by 5-bromo-
2′-deoxy-uridine (BrdU) incorporation using a 
chemioluminescence ELISA according to the 
manufacturer’s instructions (#11669915001 Roche 
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Diagnostic S.p.A, Monza, Italy). To evaluate the effect on 
A549 cells, 3 × 103 cells were seeded in 96-well plate. 
After adherence, cells were treated with Ni(SalPipNONO) 
(0.1 to 1 mM, 24 h) in presence of 0.1% e 2% FBS. 
To assay the effect on non-tumor cells on a condition 
of quiescence (to mimic a physiologic environment) 
5 × 103 cells were seeded in 96-well plate. After adherence, 
cells were treated with Ni(SalPipNONO) at 0.5 and 1 
mM for 24 h in presence of 0.1% FBS. Finally, to test the 
antiproliferative action of drug on non-tumor cells, 3 × 
103 cells were seeded in 96-well plate. After adherence, 
cells were treated with Ni(SalPipNONO) at 0.5 and 1 
mM for 24 h in presence of 2%. FBS. In all experimental 
conditions BrdU was added for the last 8 h of incubation. 
Then, cells were processed following manufacturer’s 
protocol. Chemiluminescence generated by BrdU labelled 
cells was measured using Infinite F200 Pro (Tecan Life 
Sciences, Switzerland). 
Clonogenic assay
The potential cytotoxic effect of NO donors was 
evaluated by the clonogenic assay [59]. A549 (2 × 105 
cells/well) were seeded in 6-well plates. After adherence, 
cells were treated with Ni(SalPipNONO) or DETA/NO 
(0.1 to 1 mM, 48 h). Then, cells were trypsinized, seeded 
in 24 multi-well plate at the density of 500 cells/well and 
incubated at 37° C for 10 days in medium with 1% serum. 
Colonies were fixed with methanol and stained with a 
solution of Cristal Violet in 10% methanol (Sigma Aldrich, 
St. Louis, MO, USA). Colonies formed by over 30 cells 
were counted and representative pictures were shown. 
Data are expressed as surviving fraction.
Invasion assay
Cell invasion was performed by the Boyden 
chamber technique (Neuroprobe 48-well microchemotaxis 
chamber) (BiomapSnc, Agrate B.za, MI, Italy), with the 
filter coated with gelatin (Sigma Aldrich, St. Louis, MO, 
USA) [58, 59]. 1.25 × 104 cells (A549) previously treated 
with Ni(SalPipNONO) or DETA/NO (0.5 mM, 18 h) or 
15d-PGJ2 (1–30 µM) were added to the upper wells of 
the chamber. Lower wells contained 0.1% or 10% FBS as 
chemoattractant. After 4 h of incubation, cells were fixed 
and stained with Diff-Quik kit (Biomap Snc, Agrat B.za, 
MI, Italy). Migrated cells present in 5 fields/well were 
counted at 40× original magnification. Data are reported 
as the number of countedcells/well.
ROS measurement
ROS levels were evaluated as previously reported 
[60]. A total of 1.5 × 103 cells were seeded in 96-well 
plates and, after adherence, were treated with 0.5 mM 
Ni(SalPipNONO) or Ni(SalPip) in medium without 
phenol red and different serum concentrations. NAC 
(5 mM, 30 min pretreatment) was used as a ROS 
scavenger. DCFH2-DA (2,-7-dichlorodihydrofluorescein 
diacetate; Invitrogen, Milan, Italy) was added (10 μM, 30 
min) and intracellular levels of ROS were evaluated with 
a microplate reader (excitation/emission 495/527; Infinite 
F200 Pro (TecanLifeSciences, Switzerland). The results 
are reported as relative fluorescence units (RFU) corrected 
for the cell number counted.
Western blot
Sub-confluent A549 were seeded in 6 cm diameter 
Petri dishes. After adherence, cells were treated for 
the indicated times with Ni(SalPipNONO) (0.5 mM) 
and specific pathway inhibitors. Protein extraction and 
Western blot were performed as previously described 
[58, 61]. Electrophoresis (50 μg of protein/sample) was 
carried out in 4–12% Bis-Tris Gels (Life Technologies, 
Carlsbad, CA, USA). Proteins were then blotted onto 
nitrocellulose membranes, incubated overnight with 
primary antibodies [Anti-cytochrome c, anti-phospho-
ERK1/2, anti-caspase- 3, anti-ERK antibodies from Cell 
Signaling (Celbio, Milan, Italy); anti-p53 antibody from 
Santa Cruz Biotechnology Inc (Dallas TX, USA); anti-
COX-2 from Cayman Chemical (Ann Arbor, MI, USA); 
anti-HIF-1α from BD Biosciences (San Jose, CA, USA); 
anti-VEGF from Merck KGaA (Darmstadt, Germany)] 
and then detected by enhanced chemiluminescence system 
(Biorad, Hercules, CA, USA). Results were normalized 
to those obtained by using an antibody against beta actin 
from Merck KGaA (Darmstadt, Germany) or total ERK1/2 
(Cell Signaling, Celbio, Milan, Italy), when indicated.
Endothelial survival assay
Survival of endothelial cells (HUVEC) was 
evaluated following the protocol previously reported [61]. 
1 × 103 cells/well (of 96-well multiplates) were let to 
adhere in 10% serum for 3–4 h and then VEGF (20 ng/ml) 
in presence/absence of the NO donor was added in medium 
with 0.1% serum. After 2 days, cells were fixed, stained 
and randomly counted at 20 × original magnification in 5 
fields. Data are reported as number of cell counted/well.
In vitro co-culture assay
Tumor cells (3 × 104 cells) were cultured on 
transwell inserts (12 mm diameter, polycarbonate 
membranes with 0.4 µm pores; Corning, Lowell, MA, 
USA) and treated for 24 h with 0.5 mM Ni(SalPipNONO). 
Then the inserts were transferred on top of endothelial 
cells plated on Matrigel (1.5 × 105 cells in 12-well 
multiplate) for further 18 h of incubation. At the end of 
the experiment, endothelial cells were photographed and 
network formation on Matrigel was measured by means of 
the number of complete circles (Nikon Eclipse E400 and 
camera Nikon DS-5MC).
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In vivo matrigel angiogenesis assay
Investigation has been conducted in accordance with 
the ethical standards and according to the Declaration of 
Helsinki and the Italian law (Legislative Decree no.26, 4 
March 2014), which acknowledges the European Directive 
2010/63/UE, being approved by the authors’ institutional 
review board and the Italian Ministry of Health. All efforts 
were made to minimize the number of animals used 
and their suffering. In vivo Matrigel angiogenesis assay 
was performed as previously described [32]. C57 black 
mice (20–25 g) were kept in temperature- and humidity-
controlled rooms (at 22° C) with lights on from 7 am to 
7 pm, water and food available ad libitum. VEGF (300 
ng) in presence/absence of Ni(SalPipNONO) (0.5 mM) 
was diluted in growth factor and phenol red-free Matrigel 
(Becton Dickinson, Franklin Lakes, NJ, USA) on ice. 
Mice were subcutaneously injected in the dorsal midline 
region with 0.4 ml of Matrigel. After 10 days, mice were 
euthanized and implants harvested. Plugs were re-suspended 
in 1 ml of Drabkin′s reagent (Sigma Aldrich, St. Louis, MO, 
USA) for 18 h on ice and hemoglobin concentration was 
determined by absorbance at 540 nm and compared with a 
standard curve (Sigma Aldrich, St. Louis, MO, USA).
Statistical analysis
Data represent means ± SD of at least 3 
determinations. Statistical analysis was performed by 
means of Student’s t test for unpaired data or by analysis 
of variance, followed by Bonferroni’s test for comparison 
among groups of data; p < 0.05 was considered statistically 
significant.
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